By Patricio Ledesma, CEO & Founder of Sofpromed
Table of Contents
As the CEO and Founder of Sofpromed, I regularly speak with biotechnology executives looking for the right country to conduct their next clinical trial.
For many small and emerging biotech companies, choosing the right location can significantly affect timelines, costs, patient recruitment, data quality, and ultimately the success of the entire development program.
Over the last 15 years, I have had the opportunity to work with sponsors from around the world and support clinical research projects across multiple therapeutic areas.
One conclusion has become increasingly clear: Spain has emerged as one of the most attractive and efficient countries in Europe for conducting clinical trials.
While many biotech companies initially focus on markets such as Germany, France, or the United Kingdom, they are often surprised to discover that Spain frequently offers a better combination of patient access, investigator expertise, regulatory efficiency, and cost effectiveness.
In this article, I would like to share what I consider the three most important reasons why small biotech companies should strongly consider Spain as a clinical trial destination, and why so many international sponsors continue to invest in Spanish research sites year after year.
Reason #1: Exceptional Patient Recruitment Capabilities
One of the biggest risks in any clinical trial is slow patient enrollment.
Many studies fail to meet their recruitment targets on schedule, leading to costly delays that can extend development timelines by months or even years.
For a small biotech company operating with limited funding, such delays can have serious financial consequences.
This is where Spain stands out.
Spanish investigators and research hospitals have developed a strong reputation for efficient patient recruitment across a wide range of therapeutic areas, including:
- Oncology
- Neurology
- Rare diseases
- Cardiovascular diseases
- Endocrinology
- Gastroenterology
- Dermatology
- Hematology
- Infectious diseases
Several factors contribute to this success.
Large Public Healthcare System
Spain's healthcare system provides universal access to care for the vast majority of the population.
This means patients are often concentrated within large hospital networks that maintain extensive medical databases and specialized clinical services.
As a result, investigators typically have access to clearly defined patient populations and can identify potential study candidates efficiently.
Centralized Care for Complex Diseases
Many patients with serious or rare conditions are referred to specialized university hospitals and reference centers.
This concentration of patients allows sponsors to recruit eligible subjects more quickly compared with countries where healthcare delivery is more fragmented.
Highly Motivated Investigators
Spanish principal investigators are recognized throughout Europe for their commitment to clinical research.
Many clinicians actively participate in international studies and maintain strong relationships with patient communities, helping reduce recruitment barriers and improve study awareness.
For biotech companies pursuing aggressive development timelines, fast recruitment can dramatically reduce overall development costs and accelerate key milestones.
Reason #2: World-Class Investigators and Research Institutions
Clinical trial success depends not only on recruiting patients but also on generating high-quality data.
Fortunately, Spain is home to some of Europe's most respected investigators and research institutions.
The country has invested heavily in biomedical research over the last two decades, creating strong infrastructures that support both academic and industry-sponsored studies.
Leading University Hospitals
Spain hosts numerous internationally recognized hospitals that participate regularly in global clinical development programs.
Examples include:
- Hospital Clínic Barcelona
- Vall d'Hebron University Hospital
- Hospital Universitario La Paz
- Hospital Gregorio Marañón
- Hospital Universitario 12 de Octubre
- Virgen del Rocío University Hospital
These institutions are accustomed to working under International Council for Harmonisation (ICH-GCP) standards and frequently participate in pivotal studies submitted to regulators worldwide.
Strong Scientific Expertise
Spanish investigators are highly active contributors to international medical literature and scientific congresses.
Many key opinion leaders maintain collaborations with:
- European Society for Medical Oncology (ESMO)
- European Academy of Neurology (EAN)
- European Society of Cardiology (ESC)
- American Society of Clinical Oncology (ASCO)
This scientific engagement creates an environment where investigators understand not only clinical practice but also the broader strategic objectives of drug development.
Experience with Innovative Therapies
Spain has become increasingly active in:
- Cell therapies
- Gene therapies
- Immunotherapies
- Precision medicine programs
- Advanced biologics
For emerging biotech sponsors developing innovative treatments, access to investigators familiar with novel technologies can considerably reduce operational risks.
The combination of medical expertise and research experience often translates into better protocol compliance, fewer deviations, higher-quality source documentation, and more reliable clinical data.
Reason #3: Excellent Cost-to-Quality Ratio
For small biotech companies, budget management is always a critical concern.
Every euro invested in clinical development must generate maximum value.
Spain offers one of the most attractive cost-to-quality ratios available in Europe.
Competitive Operational Costs
Although Spain maintains quality standards comparable to other major European countries, study costs are often more favorable than those seen in:
- Germany
- Switzerland
- United Kingdom
- Scandinavia
Areas where sponsors may experience savings include:
- Site management costs
- Monitoring activities
- Investigator grants
- Clinical operations support
- Vendor management
- Staffing expenses
Efficient Study Execution
Spanish sites are generally experienced in handling clinical trial processes and often require less operational oversight compared with inexperienced centers.
This efficiency can reduce:
- Monitoring burden
- Query resolution timelines
- Data cleaning efforts
- Administrative overhead
Greater Return on Development Investment
When sponsors combine competitive costs with rapid recruitment and strong data quality, the overall return on investment becomes highly attractive.
This is especially important for venture-backed biotech companies that must demonstrate progress to investors while carefully managing cash reserves.
A well-executed trial in Spain can often achieve the same scientific objectives as a trial conducted in more expensive markets, but with substantially better operational efficiency.
Additional Advantages of Conducting Clinical Trials in Spain
Beyond these three primary reasons, Spain offers several additional benefits that deserve attention.
Strong Regulatory Environment
Spain has developed a mature regulatory framework aligned with European standards.
The country's regulatory authorities and ethics committees have extensive experience reviewing complex clinical research projects.
Sponsors benefit from established processes and clear expectations regarding regulatory submissions.
High Patient Trust in Clinical Research
Spanish patients generally demonstrate positive attitudes toward participation in clinical trials.
Many patients recognize the potential benefits of accessing innovative therapies and contributing to medical advancement.
This cultural acceptance helps facilitate enrollment activities across many therapeutic areas.
Strategic European Location
Spain serves as an excellent gateway for multinational European studies.
The country combines:
- Modern infrastructure
- International airports
- Established logistics networks
- Experienced research professionals
This makes operational management straightforward for sponsors located elsewhere in Europe, North America, or Asia.
Growing Biotechnology Ecosystem
The Spanish biotechnology sector continues to expand rapidly.
Research clusters in cities such as:
- Barcelona
- Madrid
- Valencia
- Seville
- Bilbao
have created vibrant environments that support innovation and collaboration between academic institutions, hospitals, biotech companies, and service providers.
Why Small Biotech Companies Particularly Benefit from Spanish Clinical Trials
Large pharmaceutical companies often possess extensive internal infrastructure, global teams, and substantial financial resources.
Small biotech companies usually operate under very different circumstances.
They often face challenges such as:
- Limited budgets
- Small clinical operations teams
- Aggressive investor expectations
- Short development timelines
- Limited internal regulatory expertise
Because of this, every operational decision matters.
Spain offers a unique combination of:
- Fast patient recruitment
- High-quality investigators
- Competitive costs
- Strong research infrastructure
These factors help smaller organizations maximize limited resources while maintaining high scientific standards.
For many biotech companies, conducting a study in Spain can mean the difference between achieving critical milestones on time or facing costly delays.
Why Sofpromed Is an Ideal CRO Partner for Clinical Trials in Spain
Selecting the right country is important.
Selecting the right CRO partner is equally important.
At Sofpromed, we have spent more than 15 years supporting clinical trials throughout Spain, working closely with hospitals, investigators, ethics committees, and sponsors from around the world.
Our experience allows us to help biotechnology companies navigate the entire clinical development process efficiently and cost effectively.
Deep Local Knowledge
Over the years, we have built strong relationships with research centers and investigators across Spain.
We understand:
- Site capabilities
- Recruitment performance
- Therapeutic expertise
- Operational strengths
- Regulatory requirements
This allows us to identify the most suitable sites for each individual study.
Flexible Support for Small Biotech Companies
Unlike many large CROs, we understand the realities faced by emerging biotechnology companies.
We provide flexible solutions tailored to sponsor needs, whether support is required for:
- Project management
- Clinical monitoring
- Regulatory affairs
- Medical writing
- Data management
- Pharmacovigilance
- Statistical programming
- Biometrics
Our objective is to function as a true extension of the sponsor's team.
Cost-Effective Clinical Operations
We have developed operational models specifically designed to help sponsors optimize budgets without compromising quality.
By combining experienced professionals with efficient processes, we help biotechnology companies achieve high-quality results while maintaining financial discipline.
Strong Commitment to Quality
Quality remains at the center of everything we do.
Our teams operate according to international standards and focus on delivering reliable, inspection-ready clinical data.
We understand that every dataset generated today may support future regulatory submissions, partnerships, funding rounds, or product approvals.
Conclusion
For small biotechnology companies looking to maximize efficiency, control costs, and accelerate development timelines, Spain represents one of the most attractive clinical trial destinations in Europe.
The country's strengths are clear:
- Outstanding patient recruitment capabilities
- World-class investigators and research institutions
- Excellent cost-to-quality ratio
When these advantages are combined with Spain's mature clinical research ecosystem, strong healthcare infrastructure, and experienced investigators, sponsors gain a powerful environment for executing successful studies.
At Sofpromed, we have witnessed these advantages firsthand for more than 15 years.
Our mission is to help biotech innovators bring new therapies to patients faster through efficient, high-quality clinical trial management in Spain.
If you are planning a clinical study and evaluating European locations, I strongly encourage you to consider Spain.
The combination of scientific excellence, operational efficiency, and value for money makes it one of the smartest choices available today for emerging biotech companies seeking to advance their development programs with confidence.
